Home › Companies › STRO

Sutro Biopharma

Market cap $148M 16.6M shares (10-Q, Nov 6, 2026) × $8.92 close Nov 17, 2026

Most recent annual filing: 2026-03-23

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. STRO-006 IND filing2026STRO-006 IND filing, 2026, notable
  2. STRO-227 IND filing2H 2026STRO-227 IND filing, 2H 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Technology platforms

XpressCF · Vaxcyte

Cell-free protein synthesis platform enabling rapid production of complex biologics including ADCs, iADCs, bispecific ADCs, and dpADCs for oncology; also licensed to Vaxcyte for infectious disease vaccine development

XpressCF+ · Astellas

Site-specific conjugation platform enabling non-natural amino acid incorporation and precise dual-payload conjugation for homogeneous ADCs, iADCs, bispecific ADCs, and dpADCs in oncology

XpressCF

Proprietary cell-free protein synthesis platform enabling site-specific conjugation and rapid systematic evaluation of protein structure-activity relationships to create optimized homogeneous ADC, bispecific ADC, iADC, and dual-payload ADC product candidates; focus area: oncology

Discontinued (2)

Capital (as filed)

Cash
$46.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$95.3M Sep 30, 2026
Operating cash flow
−$22.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$142M cash, runway into the first half of 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Sutro Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Sutro Biopharma (STRO) - Scientific Deep Dive for Lead and Pipeline Products Sutro's cell-free ADC platform offers a differentiated safety profile with a mid-2026 STRO-004 Phase 1 readout as a make-or-break binary catalyst, with the February 2026 financing removing near-term dilution risk.
  2. Buy core UPDATE: Sutro Biopharma (STRO) - The Binary Event Landed STRO-004's Phase 1 data confirmed the safety and PK hypothesis — 12% epistaxis vs. ~70% for Tivdak, 98% DAR8 retention, and CMO execution validated — upgrading from speculative to core buy despite efficacy remaining unquantified.
  3. Buy core UPDATE: Sutro Biopharma (STRO) - Priced Near Cash Despite a 55% decline since the August BUY call, the STRO-004 safety thesis is unchanged, the market cap is near cash value, and the 1H 2027 catalyst remains intact — though an active ATM and admitted CMO friction are real risks.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

16 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)